Haleon plc
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brian James McNamara
- Full Time Employees
- 24,535
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- The Heights Weybridge SU United Kingdom KT13 0NY
- IPO Date
- Jul 25, 2022
- CIK
- 0001900304
- Website
- haleon.com
- Similar Companies
- Business
- Haleon plc operates as a leading consumer healthcare company focused on everyday health products across six core categories: oral health, vitamins minerals and supplements (VMS), pain relief, respiratory health, digestive health, and therapeutic skin health; its portfolio features market-leading brands such as Sensodyne, Parodontax and Polident for toothpaste, denture care and gum health; Centrum, Emergen-C and Caltrate for multivitamins, vitamin C and calcium supplements; Advil, Panadol and Voltaren for pain relief and anti-inflammatory treatments; Otrivin, Theraflu, Flonase, Contac and Beechams for cold, flu, nasal congestion, coughs and allergies; Tums, ENO and Benefiber for heartburn, acid indigestion and fiber supplementation; and Fenistil, Zovirax and Bactroban for skin treatments. The company, founded through a 2022 spin-off from GlaxoSmithKline's consumer healthcare business and tracing roots to 1715, maintains headquarters in Weybridge, England, and conducts operations in over 170 markets worldwide, including key segments in North America, Europe Middle East Africa and Latin America (EMEA & LatAm), and Asia Pacific (APAC), serving more than one billion consumers and health professionals. Haleon plc recently completed the acquisition of the remaining 12% equity interest in its China joint venture Tianjin TSKF Pharmaceutical Co Ltd in June 2025 for approximately 200 million pounds, establishing TSKF as a wholly owned subsidiary that manufactures and distributes brands like Fenbid, Voltaren and Bactroban and represented about 40% of its China revenues in 2024; earlier in September 2024 it finalized the divestiture of its non-US nicotine replacement therapy business to Dr Reddy's Laboratories for 458 million pounds upfront plus up to 42 million pounds in contingent payments; and in March 2025 Pfizer fully exited its remaining stake for about 2.5 billion pounds following prior reductions.
Company News
Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs
LCUT or HLN: Which Is the Better Value Stock Right Now?
Haleon secures better shelf space at Walmart, Target in bid to boost market share
Comparing Haleon (NYSE:HLN) & Procter & Gamble (NYSE:PG)
LCUT vs. HLN: Which Stock Is the Better Value Option?
Jefferies raises Haleon price target to 410p on margin strength
Haleon plc: Announces Pricing Terms, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes
Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes
Haleon plc (LON:HLN) Receives Average Recommendation of “Hold” from Analysts
Haleon plc (HLN) Q2 2026 Earnings Call Prepared Remarks Transcript
ACCO vs. HLN: Which Stock Is the Better Value Option?
Haleon slides as quality of growth questioned
Haleon plc (HLN) Q2 2026 Earnings Call Transcript
Bank of New York Mellon Corp Has $25.99 Million Stock Position in Haleon PLC Sponsored ADR $HLN
FTSE 100 shares to watch: Lloyds, Barclays, IAG, NatWest, GSK, AstraZeneca
LCUT vs. HLN: Which Stock Is the Better Value Option?
Haleon Bets on Microsoft AI To Support Growth and Reach One Billion More Consumers by 2030
Haleon to Accelerate AI-powered Transformation With New Five-year Microsoft Collaboration
Nasdaq leads Wall Street higher at the open as uneasy Iran truce holds
Futura swaps Haleon for Market Performance Group to drive US Eroxon sales - UPDATE